Key facts
- It has raised $3.2M; the latest was Accelerator/Incubator in Jun 2025.
- Notable investors include Tech Incubator Program for Startup, Posco Investment, Shinhan Capital, KB Securities, A Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for MXBIO
- ·The full record, as it builds
Funding rounds
No funding rounds for MXBIO are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MXBIO
Developer of periodontal disease treatment drugs designed to offer periodontal disease treatment. The company develops drugs for periodontal disease, an infection of the tissues that hold teeth in place which causes inflammation in the gums, enabling patients to be healthy.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2018
- Employees
- 13
- Website
- mx-bio.com/
- Ownership
- Privately Held (backing)
MXBIO doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MXBIO shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MXBIO in its N-PORT filings yet. We sweep new filings monthly.